U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec et al., Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non???Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial, Journal of Clinical Oncology, vol.25, issue.12, pp.1545-52, 2007.
DOI : 10.1200/JCO.2005.05.1474

A. F. Gazdar, Signaling in Lung Cancer, New England Journal of Medicine, vol.361, issue.10, pp.1018-1038, 2009.
DOI : 10.1056/NEJMe0905763

S. Gazzeri, V. Gouyer, C. Vour-'ch, C. Brambilla, and E. Brambilla, Mechanisms of p16INK4A inactivation in non small-cell lung cancers, Oncogene, vol.16, issue.4, pp.497-504, 1998.
DOI : 10.1038/sj.onc.1201559

R. Gerl and D. L. Vaux, Apoptosis in the development and treatment of cancer, Carcinogenesis, vol.26, issue.2, pp.263-70, 2005.
DOI : 10.1093/carcin/bgh283

G. Giaccone, R. S. Herbst, C. Manegold, G. Scagliotti, R. Rosell et al., Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non???Small-Cell Lung Cancer: A Phase III Trial???INTACT 1, Journal of Clinical Oncology, vol.22, issue.5, pp.777-84, 2004.
DOI : 10.1200/JCO.2004.08.001

N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model, Clin Cancer Res, vol.1, issue.11, pp.1311-1319, 1995.

A. Gschwind, O. M. Fischer, and A. Ullrich, Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy, Nature Reviews Cancer, vol.4, issue.5, pp.361-70, 2004.
DOI : 10.1038/nrc1360

A. Gschwind, S. Hart, O. M. Fischer, and A. Ullrich, TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells, The EMBO Journal, vol.22, issue.10, 2003.
DOI : 10.1093/emboj/cdg231

C. Gullo, M. Au, G. Feng, and G. Teoh, The biology of Ku and its potential oncogenic role in cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1765, issue.2, 2006.
DOI : 10.1016/j.bbcan.2006.01.001

P. Haluska, J. M. Carboni, C. Teneyck, R. M. Attar, X. Hou et al., HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924, Molecular Cancer Therapeutics, vol.7, issue.9, pp.536924-2589, 2008.
DOI : 10.1158/1535-7163.MCT-08-0493

S. W. Han, T. Y. Kim, Y. K. Jeon, P. G. Hwang, S. A. Im et al., Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation, Clinical Cancer Research, vol.12, issue.8, pp.2538-2582, 2006.
DOI : 10.1158/1078-0432.CCR-05-2845

D. Hanahan and R. A. Weinberg, The hallmarks of cancer. Cell, pp.57-70, 2000.

T. Hanaoka, J. Nakayama, J. Mukai, S. Irie, T. Yamanda et al., Association of smoking with apoptosis???regulated proteins (Bcl???2, Bax and p53) in resected non???small???cell lung cancers, International Journal of Cancer, vol.91, issue.2, pp.267-276, 2001.
DOI : 10.1002/1097-0215(200002)9999:9999<::AID-IJC1030>3.3.CO;2-V

N. Hanna, R. Lilenbaum, R. Ansari, T. Lynch, R. Govindan et al., Phase II Trial of Cetuximab in Patients With Previously Treated Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.24, issue.33, pp.5253-5261, 2006.
DOI : 10.1200/JCO.2006.08.2263

E. B. Haura, Z. Zheng, L. Song, A. Cantor, and G. Bepler, Activated Epidermal Growth Factor Receptor-Stat-3 Signaling Promotes Tumor Survival In vivo in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.11, issue.23, pp.8288-94, 2005.
DOI : 10.1158/1078-0432.CCR-05-0827

S. S. Hecht, Tobacco carcinogens, their biomarkers and tobacco-induced cancer, Nature Reviews Cancer, vol.3, issue.10, pp.733-777, 2003.
DOI : 10.1038/nrc1190

S. S. Hecht, F. Kassie, and D. K. Hatsukami, Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers, Nature Reviews Cancer, vol.62, issue.7, pp.476-88, 2009.
DOI : 10.1038/nrc2674

M. O. Hengartner, The biochemistry of apoptosis, Nature, vol.407, issue.6805, pp.770-776, 2000.
DOI : 10.1038/35037710

R. S. Herbst, G. Giaccone, J. H. Schiller, R. B. Natale, V. Miller et al., Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non???Small-Cell Lung Cancer: A Phase III Trial???INTACT 2, Journal of Clinical Oncology, vol.22, issue.5, pp.785-94, 2004.
DOI : 10.1200/JCO.2004.07.215

R. S. Herbst, S. Yano, H. Kuniyasu, F. R. Khuri, C. D. Bucana et al., Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma, Clin Cancer Res, vol.6, issue.3, pp.790-797, 2000.

I. Herr and K. M. Debatin, Cellular stress response and apoptosis in cancer therapy, Blood, vol.98, issue.9, pp.2603-2617, 2001.
DOI : 10.1182/blood.V98.9.2603

F. R. Évolution-de-la-mortalité-hirsch, M. Varella-garcia, P. A. Bunn, . Jr, W. A. Franklin et al., Saint-Maurice (Fra) : Institut de veille sanitaire.; 272p Disponible sur: www.invs.santé Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-smallcell lung cancer, J Clin Oncol, vol.24, issue.31, pp.5034-5076, 1950.

F. R. Hirsch and S. Witta, Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer, Current Opinion in Oncology, vol.17, issue.2, pp.118-140, 2005.
DOI : 10.1097/01.cco.0000155059.39733.9d

K. Miyado, A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membraneanchored heparin-binding EGF-like growth factor, Embo J, vol.17, issue.24, pp.7260-72, 1998.

P. A. Janne, J. Von-pawel, R. B. Cohen, L. Crino, C. A. Butts et al., Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.25, pp.3936-3980, 2007.
DOI : 10.1200/JCO.2007.11.1336

G. R. Johnson, T. Saeki, A. W. Gordon, M. Shoyab, D. S. Salomon et al., Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon, The Journal of Cell Biology, vol.118, issue.3, pp.741-51, 1992.
DOI : 10.1083/jcb.118.3.741

H. E. Jones, J. M. Gee, D. Barrow, D. Tonge, B. Holloway et al., Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells, British Journal of Cancer, vol.16, issue.2, 2006.
DOI : 10.1210/en.132.3.1132

H. E. Jones, L. Goddard, J. M. Gee, S. Hiscox, M. Rubini et al., Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells, Endocrine Related Cancer, vol.11, issue.4, 2004.
DOI : 10.1677/erc.1.00799

R. N. Jorissen, F. Walker, N. Pouliot, T. P. Garrett, C. W. Ward et al., Epidermal growth factor receptor: mechanisms of activation and signalling, Experimental Cell Research, vol.284, issue.1, 2003.
DOI : 10.1016/S0014-4827(02)00098-8

D. S. Ju, M. J. Kim, J. H. Bae, H. S. Song, B. S. Chung et al., Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells, Cancer Letters, vol.252, issue.1, pp.75-85, 2007.
DOI : 10.1016/j.canlet.2006.12.013

S. Kakiuchi, Y. Daigo, N. Ishikawa, C. Furukawa, T. Tsunoda et al., Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839), Human Molecular Genetics, vol.13, issue.24, pp.3029-3072, 2004.
DOI : 10.1093/hmg/ddh331

I. Kalomenidis, D. Orphanidou, G. Papamichalis, T. Vassilakopoulos, A. Scorilas et al., Combined Expression of p53, Bcl-2, and p21WAF-1 Proteins in Lung Cancer and Premalignant Lesions: Association with Clinical Characteristics, Lung, vol.179, issue.5, pp.265-78, 2001.
DOI : 10.1007/s004080010067

K. Kamemura, A. Ito, T. Shimazu, A. Matsuyama, S. Maeda et al., Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells, Biochemical and Biophysical Research Communications, vol.374, issue.1, pp.84-93, 2008.
DOI : 10.1016/j.bbrc.2008.06.092

O. Kargiotis, C. Chetty, C. S. Gondi, A. J. Tsung, D. H. Dinh et al., Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma, Oncogene, vol.20, issue.35, pp.4830-4870, 2008.
DOI : 10.1038/onc.2008.122

M. Kato, T. Inazu, Y. Kawai, K. Masamura, M. Yoshida et al., Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5, Biochemical and Biophysical Research Communications, vol.301, issue.4, pp.7-12, 2003.
DOI : 10.1016/S0006-291X(03)00093-7

S. H. Kaufmann and W. C. Earnshaw, Induction of Apoptosis by Cancer Chemotherapy, Experimental Cell Research, vol.256, issue.1, pp.42-51, 2000.
DOI : 10.1006/excr.2000.4838

S. H. Kaufmann and D. L. Vaux, Alterations in the apoptotic machinery and their potential role in anticancer drug resistance, Oncogene, vol.22, issue.47, pp.7414-7444, 2003.
DOI : 10.1038/sj.onc.1206945

S. Khambata-ford, C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison et al., Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007.
DOI : 10.1200/JCO.2006.10.5437

E. S. Kim, V. Hirsh, T. Mok, M. A. Socinski, R. Gervais et al., Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, The Lancet, vol.372, issue.9652, pp.1809-1827, 2008.
DOI : 10.1016/S0140-6736(08)61758-4

H. Kimura, M. Suminoe, K. Kasahara, T. Sone, T. Araya et al., Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA), British Journal of Cancer, vol.97, issue.6, pp.778-84, 2007.
DOI : 10.1038/11751

R. Koomagi and M. Volm, Expression of FAS (CD95/APO???1) and FAS ligand in lung cancer, its prognostic and predictive relevance, International Journal of Cancer, vol.84, issue.3, pp.239-282, 1999.
DOI : 10.1002/(SICI)1097-0215(19990621)84:3<239::AID-IJC7>3.3.CO;2-J

T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida et al., Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib, Clinical Cancer Research, vol.12, issue.19, pp.5764-5773, 2006.
DOI : 10.1158/1078-0432.CCR-06-0714

D. S. Krause and R. A. Van-etten, Tyrosine Kinases as Targets for Cancer Therapy, New England Journal of Medicine, vol.353, issue.2, pp.172-87, 2005.
DOI : 10.1056/NEJMra044389

M. G. Kris, R. B. Natale, R. S. Herbst, T. J. Lynch, . Jr et al., Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non???Small Cell Lung Cancer, JAMA, vol.290, issue.16, pp.2149-58, 2003.
DOI : 10.1001/jama.290.16.2149

S. Lantuejoul, B. Constantin, H. Drabkin, C. Brambilla, J. Roche et al., Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines, The Journal of Pathology, vol.62, issue.3, pp.336-383, 2003.
DOI : 10.1002/path.1367

S. Lantuejoul, C. Salon, J. C. Soria, and E. Brambilla, Telomerase expression in lung preneoplasia and neoplasia, International Journal of Cancer, vol.295, issue.9, pp.1835-1876, 2007.
DOI : 10.1002/ijc.22473
URL : https://hal.archives-ouvertes.fr/inserm-00173051

A. Lautrette, S. Li, R. Alili, S. W. Sunnarborg, M. Burtin et al., Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach, Nature Medicine, vol.100, issue.8, pp.867-74, 2005.
DOI : 10.1074/jbc.M001965200

J. Taniere and P. , TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers, Cancer Res, vol.65, issue.12, pp.5076-83, 2005.

L. Faou, A. L. Scemama, and O. , [Epidemiology of tobacco smoking], Rev Mal Respir, vol.22, issue.6 2, pp.8-27, 2005.

L. Tourneau, C. Vidal, L. Siu, and L. L. , Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents, Drug Resistance Updates, vol.11, issue.3, pp.99-109, 2008.
DOI : 10.1016/j.drup.2008.04.001

S. H. Lee, M. S. Shin, H. S. Kim, H. K. Lee, W. S. Park et al., Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers, Cancer Res, vol.59, issue.22, pp.5683-5689, 1999.

S. M. Lee, J. H. Bae, M. J. Kim, H. S. Lee, M. K. Lee et al., Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors, Journal of Pharmacology and Experimental Therapeutics, vol.322, issue.3, pp.1084-92, 2007.
DOI : 10.1124/jpet.107.124461

H. Lemjabbar, D. Li, M. Gallup, S. Sidhu, E. Drori et al., Tobacco Smoke-induced Lung Cell Proliferation Mediated by Tumor Necrosis Factor ??-converting Enzyme and Amphiregulin, Journal of Biological Chemistry, vol.278, issue.28, pp.26202-26209, 2003.
DOI : 10.1074/jbc.M207018200

B. Levine and G. Kroemer, Autophagy in the Pathogenesis of Disease, Cell, vol.132, issue.1, pp.27-42, 2008.
DOI : 10.1016/j.cell.2007.12.018

C. Li, M. Iida, E. F. Dunn, A. J. Ghia, and D. L. Wheeler, Nuclear EGFR contributes to acquired resistance to cetuximab, Oncogene, vol.8, issue.43, 2009.
DOI : 10.1038/35052073
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900381

G. C. Li, F. He, X. Shao, M. Urano, L. Shen et al., Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo, Cancer Res, vol.63, issue.12, pp.3268-74, 2003.

G. C. Li, H. Ouyang, X. Li, H. Nagasawa, J. B. Little et al., Ku70, Molecular Cell, vol.2, issue.1, pp.1-8, 1998.
DOI : 10.1016/S1097-2765(00)80108-2
URL : http://doi.org/10.1016/s1097-2765(00)80108-2

L. Y. Li, X. Luo, and X. Wang, Endonuclease G is an apoptotic DNase when released from mitochondria, Nature, vol.412, issue.6842, pp.95-104, 2001.
DOI : 10.1038/35083620

S. Li, G. D. Plowman, S. D. Buckley, and G. D. Shipley, Heparin inhibition of autonomous growth implicates amphiregulin as an autocrine growth factor for normal human mammary epithelial cells, Journal of Cellular Physiology, vol.48, issue.1, pp.103-114, 1992.
DOI : 10.1002/jcp.1041530114

S. Li, K. R. Schmitz, P. D. Jeffrey, J. J. Wiltzius, P. Kussie et al., Structural basis for inhibition of the epidermal growth factor receptor by cetuximab, Cancer Cell, vol.7, issue.4, pp.301-312, 2005.
DOI : 10.1016/j.ccr.2005.03.003

R. B. Lichtner, A. Menrad, A. Sommer, U. Klar, and M. R. Schneider, Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors, Cancer Res, vol.61, issue.15, pp.5790-5795, 2001.

R. Lilenbaum, R. Axelrod, S. Thomas, A. Dowlati, L. Seigel et al., Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non???Small-Cell Lung Cancer and a Performance Status of 2, Journal of Clinical Oncology, vol.26, issue.6, pp.863-872, 2008.
DOI : 10.1200/JCO.2007.13.2720

R. C. Lilenbaum, The Evolving Role of Cetuximab in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.12, issue.14, pp.4432-4435, 2006.
DOI : 10.1158/1078-0432.CCR-06-0097

H. Linardou, I. J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos et al., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, The Lancet Oncology, vol.9, issue.10, pp.962-72, 2008.
DOI : 10.1016/S1470-2045(08)70206-7

Y. H. Ling, R. Lin, and R. Perez-soler, Erlotinib Induces Mitochondrial-Mediated Apoptosis in Human H3255 Non-Small-Cell Lung Cancer Cells with Epidermal Growth Factor ReceptorL858R Mutation through Mitochondrial Oxidative Phosphorylation-Dependent Activation of BAX and BAK, Molecular Pharmacology, vol.74, issue.3, pp.793-806, 2008.
DOI : 10.1124/mol.107.044396

P. Liston, W. G. Fong, and R. G. Korneluk, The inhibitors of apoptosis: there is more to life than Bcl2, Oncogene, vol.22, issue.53, pp.8568-80, 2003.
DOI : 10.1038/sj.onc.1207101

H. W. Lo, S. C. Hsu, M. Ali-seyed, M. Gunduz, W. Xia et al., Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway, Cancer Cell, vol.7, issue.6, pp.575-89, 2005.
DOI : 10.1016/j.ccr.2005.05.007

R. A. Lockshin and Z. Zakeri, Programmed cell death and apoptosis: origins of the theory, Nature Reviews Molecular Cell Biology, vol.8, issue.7, pp.545-50, 2001.
DOI : 10.1038/35080097

M. Lorente, A. Carracedo, S. Torres, F. Natali, A. Egia et al., Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis, Glia, vol.14, issue.13, 2009.
DOI : 10.1002/glia.20856

D. Lu, H. Zhang, H. Koo, J. Tonra, P. Balderes et al., A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity, Journal of Biological Chemistry, vol.280, issue.20, pp.19665-72, 2005.
DOI : 10.1074/jbc.M500815200

D. Lu, H. Zhang, D. Ludwig, A. Persaud, X. Jimenez et al., Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody, Journal of Biological Chemistry, vol.279, issue.4, pp.2856-65, 2004.
DOI : 10.1074/jbc.M310132200

V. Ludovini, G. Bellezza, L. Pistola, F. Bianconi, D. Carlo et al., High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients, Annals of Oncology, vol.20, issue.5, pp.842-851, 2009.
DOI : 10.1093/annonc/mdn727

N. C. Luetteke, T. H. Qiu, S. E. Fenton, K. L. Troyer, R. F. Riedel et al., Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development, Development, vol.126, issue.12, pp.2739-50, 1999.

L. Ma, A. De-roquancourt, P. Bertheau, S. Chevret, G. Millot et al., Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions, The Journal of Pathology, vol.33, issue.4, pp.413-422, 2001.
DOI : 10.1002/path.902

R. Calvo and F. , Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line, Oncogene, vol.18, issue.47, pp.6513-6533, 1999.

J. Madelaine and G. Zalcman, Biologie des cancers bronchiques. EMC-pneumologie, pp.1-8, 2005.
DOI : 10.1016/j.emcpn.2004.10.002

D. Mahalingam, A. Mita, M. M. Mita, S. T. Nawrocki, and F. J. Giles, Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development, Current Problems in Cancer, vol.33, issue.2, pp.73-111, 2009.
DOI : 10.1016/j.currproblcancer.2009.03.001

B. Martin, M. Paesmans, T. Berghmans, F. Branle, L. Ghisdal et al., Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis, British Journal of Cancer, vol.27, issue.1, pp.55-64, 2003.
DOI : 10.1016/S0169-5002(00)00105-7

N. Martini, Surgical treatment of non-small cell lung cancer by stage, Seminars in Surgical Oncology, vol.36, issue.5, pp.248-54, 1990.
DOI : 10.1002/ssu.2980060505

K. Masago, S. Fujita, Y. Hatachi, A. Fukuhara, K. Sakuma et al., Clinical significance of pretreatment serum amphiregulin and transforming growth factor-??, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer, Cancer Science, vol.17, issue.11, pp.2295-301, 2008.
DOI : 10.1111/j.1349-7006.2008.00931.x

E. Massarelli, M. Varella-garcia, X. Tang, A. C. Xavier, N. C. Ozburn et al., KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer, Clinical Cancer Research, vol.13, issue.10, pp.2890-2896, 2007.
DOI : 10.1158/1078-0432.CCR-06-3043

M. Matsui, J. Miyasaka, K. Hamada, Y. Ogawa, M. Hiramoto et al., Influence of aging and cell senescence on telomerase activity in keratinocytes, Journal of Dermatological Science, vol.22, issue.2, pp.80-87, 2000.
DOI : 10.1016/S0923-1811(99)00049-3

M. P. Mattson, Pathways towards and away from Alzheimer's disease, Nature, vol.22, issue.7000, pp.631-640, 2004.
DOI : 10.1016/j.molcel.2003.08.005

S. Mazumder, D. Plesca, M. Kinter, and A. Almasan, Interaction of a Cyclin E Fragment with Ku70 Regulates Bax-Mediated Apoptosis, Molecular and Cellular Biology, vol.27, issue.9, pp.3511-3531, 2007.
DOI : 10.1128/MCB.01448-06

S. Menashi, M. Serova, L. Ma, S. Vignot, S. Mourah et al., Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells, Cancer Res, vol.63, issue.22, pp.7575-80, 2003.

S. Menzo, M. Clementi, E. Alfani, P. Bagnarelli, S. Iacovacci et al., Trans-Activation of Epidermal Growth Factor Receptor Gene by the Hepatitis B Virus X-Gene Product, Virology, vol.196, issue.2, pp.878-82, 1993.
DOI : 10.1006/viro.1993.1550

D. T. Merrick, J. Haney, S. Petrunich, M. Sugita, Y. E. Miller et al., Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis, Lung Cancer, vol.48, issue.1, pp.31-45, 2005.
DOI : 10.1016/j.lungcan.2004.07.049

O. Micheau, A. Hammann, E. Solary, and M. T. Dimanche-boitrel, STAT-1-Independent Upregulation of FADD and Procaspase-3 and -8 in Cancer Cells Treated with Cytotoxic Drugs, Biochemical and Biophysical Research Communications, vol.256, issue.3, pp.603-610, 1999.
DOI : 10.1006/bbrc.1999.0391

O. Micheau, E. Solary, A. Hammann, and M. T. Dimanche-boitrel, Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs, Journal of Biological Chemistry, vol.274, issue.12, pp.7987-92, 1999.
DOI : 10.1074/jbc.274.12.7987

P. J. Miettinen, J. E. Berger, J. Meneses, Y. Phung, R. A. Pedersen et al., Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor, Nature, vol.376, issue.6538, pp.337-378, 1995.
DOI : 10.1038/376337a0

W. E. Miller, H. S. Earp, and N. Raab-traub, The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor, J Virol, vol.69, issue.7, pp.4390-4398, 1995.

T. Miyashita, S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin et al., Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo, Oncogene, vol.9, issue.6, pp.1799-805, 1994.

M. K. Mohamed, S. Ramalingam, Y. Lin, W. Gooding, and C. P. Belani, Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer, Annals of Oncology, vol.16, issue.5, pp.780-785, 2005.
DOI : 10.1093/annonc/mdi157

T. S. Mok, Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu et al., Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009.
DOI : 10.1056/NEJMoa0810699

U. M. Moll, S. Wolff, D. Speidel, and W. Deppert, Transcription-independent pro-apoptotic functions of p53, Current Opinion in Cell Biology, vol.17, issue.6, pp.631-637, 2005.
DOI : 10.1016/j.ceb.2005.09.007

F. Morgillo, W. Y. Kim, E. S. Kim, F. Ciardiello, W. K. Hong et al., Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non small Cell Lung Cancer Cells to Treatment with Gefitinib, Clinical Cancer Research, vol.13, issue.9, pp.2795-803, 2007.
DOI : 10.1158/1078-0432.CCR-06-2077

F. Morgillo, J. K. Woo, E. S. Kim, W. K. Hong, and H. Y. Lee, Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib, Cancer Research, vol.66, issue.20, pp.10100-10111, 2006.
DOI : 10.1158/0008-5472.CAN-06-1684

D. K. Moscatello, M. Holgado-madruga, A. K. Godwin, G. Ramirez, G. Gunn et al., Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors, Cancer Res, vol.55, issue.23, pp.5536-5545, 1995.

N. H. Myong, Tissue Microarray Analysis of Fas and FasL Expressions in Human Non-small Cell Lung Carcinomas; with Reference to the p53 and bcl-2 Overexpressions, Journal of Korean Medical Science, vol.20, issue.5, pp.770-776, 2005.
DOI : 10.3346/jkms.2005.20.5.770

S. M. Nabha, S. Glaros, M. Hong, A. E. Lykkesfeldt, R. Schiff et al., Upregulation of PKC-?? contributes to antiestrogen resistance in mammary tumor cells, Oncogene, vol.3, issue.19, pp.3166-76, 2005.
DOI : 10.1038/sj.onc.1208502

R. Nahta, L. X. Yuan, B. Zhang, R. Kobayashi, and F. J. Esteva, Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells, Cancer Research, vol.65, issue.23, pp.11118-11146, 2005.
DOI : 10.1158/0008-5472.CAN-04-3841

Y. Nambu, S. J. Hughes, A. Rehemtulla, D. Hamstra, M. B. Orringer et al., Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas., Journal of Clinical Investigation, vol.101, issue.5, pp.1102-1112, 1998.
DOI : 10.1172/JCI1692

N. Normanno, C. Bianco, A. De-luca, and D. S. Salomon, The role of EGF-related peptides in tumor growth, Frontiers in Bioscience, vol.6, issue.3, pp.685-707, 2001.
DOI : 10.2741/A635

N. Normanno, A. De-luca, C. Bianco, L. Strizzi, M. Mancino et al., Epidermal growth factor receptor (EGFR) signaling in cancer, Gene, vol.366, issue.1, pp.2-16, 2006.
DOI : 10.1016/j.gene.2005.10.018

N. Normanno, M. P. Selvam, C. Bianco, V. Damiano, E. De-angelis et al., Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line, International Journal of Cancer, vol.47, issue.6, pp.762-768, 1995.
DOI : 10.1002/ijc.2910620619

N. Normanno, M. P. Selvam, C. F. Qi, T. Saeki, G. Johnson et al., Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells., Proceedings of the National Academy of Sciences, vol.91, issue.7, pp.2790-2794, 1994.
DOI : 10.1073/pnas.91.7.2790

O. Hagan, R. C. Hassell, and J. A. , The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase, Oncogene, vol.16, issue.3, pp.301-311, 1998.
DOI : 10.1038/sj.onc.1201547

H. Okada and T. W. Mak, Pathways of apoptotic and non-apoptotic death in tumour cells, Nature Reviews Cancer, vol.21, issue.8, pp.592-603, 2004.
DOI : 10.1038/nrc1412

M. A. Olayioye, I. Beuvink, K. Horsch, J. M. Daly, and N. E. Hynes, ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases, Journal of Biological Chemistry, vol.274, issue.24, pp.17209-17227, 1999.
DOI : 10.1074/jbc.274.24.17209

M. A. Olayioye, R. M. Neve, H. A. Lane, and N. E. Hynes, NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer, The EMBO Journal, vol.19, issue.13, pp.3159-67, 2000.
DOI : 10.1093/emboj/19.13.3159

D. Ornskov, E. Nexo, and B. S. Sorensen, Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system, FEBS Journal, vol.20, issue.23, pp.5479-89, 2006.
DOI : 10.1080/00365519950185715

J. P. Overholser, M. C. Prewett, A. T. Hooper, H. W. Waksal, and D. J. Hicklin, Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer, pp.74-82, 2000.

J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich et al., EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy, Science, vol.304, issue.5676, pp.1497-500, 2004.
DOI : 10.1126/science.1099314

W. Pao, T. Y. Wang, G. J. Riely, V. A. Miller, Q. Pan et al., KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib, PLoS Medicine, vol.104, issue.1, 2005.
DOI : 10.1371/journal.pmed.0020017.sd003

D. Patel, R. Bassi, A. Hooper, M. Prewett, D. J. Hicklin et al., Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation, Int J Oncol, vol.34, issue.1, pp.25-32, 2009.

X. H. Peng, P. Karna, Z. Cao, B. H. Jiang, M. Zhou et al., Cross-talk between Epidermal Growth Factor Receptor and Hypoxia-inducible Factor-1?? Signal Pathways Increases Resistance to Apoptosis by Up-regulating Survivin Gene Expression, Journal of Biological Chemistry, vol.281, issue.36, pp.25903-25917, 2006.
DOI : 10.1074/jbc.M603414200

R. Perez-soler, HER1/EGFR Targeting: Refining the Strategy, The Oncologist, vol.9, issue.1, pp.58-67, 2004.
DOI : 10.1634/theoncologist.9-1-58

R. Perez-soler, Rash as a Surrogate Marker for Efficacy of Epidermal Growth Factor Receptor Inhibitors in Lung Cancer, Clinical Lung Cancer, vol.8, pp.7-14, 2006.
DOI : 10.3816/CLC.2006.s.008

R. Peto, S. Darby, H. Deo, P. Silcocks, E. Whitley et al., Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies, BMJ, vol.321, issue.7257, pp.323-332, 2000.
DOI : 10.1136/bmj.321.7257.323

V. Picihard, Y. Berthois, M. Roccabianca, C. Prevot, M. Sarrazin et al., Concomitant cell growth and differentiation are dependent on erbB1 and integrin activation in an autonomously surviving colon adenocarcinoma: involvement of autocrine amphiregulin secretion, Anticancer Res, vol.26, issue.4B, pp.2769-83, 2006.

M. J. Pinkoski and D. R. Green, Lymphocyte apoptosis: refining the paths to perdition, Current Opinion in Hematology, vol.9, issue.1, pp.43-52, 2002.
DOI : 10.1097/00062752-200201000-00008

R. Pirker, J. R. Pereira, A. Szczesna, J. Von-pawel, M. Krzakowski et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, The Lancet, vol.373, issue.9674, pp.1525-1556, 2009.
DOI : 10.1016/S0140-6736(09)60569-9
URL : https://hal.archives-ouvertes.fr/hal-00596921

R. M. Pitti, S. A. Marsters, D. A. Lawrence, M. Roy, F. C. Kischkel et al., Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer, Nature, vol.396, issue.6712, pp.699-703, 1998.

G. D. Plowman, J. M. Green, V. L. Mcdonald, M. G. Neubauer, C. M. Disteche et al., The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity., Molecular and Cellular Biology, vol.10, issue.5, pp.1969-81, 1990.
DOI : 10.1128/MCB.10.5.1969

M. Pollak, Insulin and insulin-like growth factor signalling in neoplasia, Nature Reviews Cancer, vol.5, issue.12, pp.915-943, 2008.
DOI : 10.2174/156800907781386623

M. C. Prewett, A. T. Hooper, R. Bassi, L. M. Ellis, H. W. Waksal et al., Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts, Clin Cancer Res, vol.8, issue.5, pp.994-1003, 2002.

N. Puri and R. Salgia, Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer, Journal of Carcinogenesis, vol.7, issue.1, 2008.
DOI : 10.4103/1477-3163.44372

Q. Qin, K. Patil, and S. C. Sharma, The role of Bax-inhibiting peptide in retinal ganglion cell apoptosis after optic nerve transection, Neuroscience Letters, vol.372, issue.1-2, pp.17-21, 2004.
DOI : 10.1016/j.neulet.2004.08.075

B. Quantin and R. Breathnach, Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts, Nature, vol.334, issue.6182, pp.538-547, 1988.
DOI : 10.1038/334538a0

W. K. Rapport-emea, R. W. Johnstone, and H. M. Prince, Histone deacetylase inhibitors in cancer therapy, Expert Opin Investig Drugs, vol.16, issue.5, pp.659-78, 2007.

A. G. Recchia, A. M. Musti, M. Lanzino, M. L. Panno, E. Turano et al., A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells, The International Journal of Biochemistry & Cell Biology, vol.41, issue.3, pp.603-617, 2009.
DOI : 10.1016/j.biocel.2008.07.004

M. Reck and L. Crino, Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer, Lung Cancer, vol.63, issue.1, pp.1-9, 2009.
DOI : 10.1016/j.lungcan.2008.05.015

J. C. Reed, Dysregulation of Apoptosis in Cancer, Journal of Clinical Oncology, vol.17, issue.9, pp.2941-53, 1999.
DOI : 10.1200/JCO.1999.17.9.2941

S. J. Reich, J. Fosnot, A. Kuroki, W. Tang, X. Yang et al., Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model, Mol Vis, vol.9, pp.210-216, 2003.

F. Ricci, S. Pucci, F. Sesti, F. Missiroli, L. Cerulli et al., Modulation of Ku70/80, Clusterin/ApoJ Isoforms and Bax Expression in Indocyanine-Green-Mediated Photo-Oxidative Cell Damage, Ophthalmic Research, vol.39, issue.3, pp.164-73, 2007.
DOI : 10.1159/000103236

J. M. Ricono, M. Huang, L. A. Barnes, S. K. Lau, S. M. Weis et al., Specific Cross-talk between Epidermal Growth Factor Receptor and Integrin ??v??5 Promotes Carcinoma Cell Invasion and Metastasis, Cancer Research, vol.69, issue.4, pp.1383-91, 2009.
DOI : 10.1158/0008-5472.CAN-08-3612

J. Rinehart, G. Wilding, J. Willson, S. Krishnamuhrti, R. Natale et al., A phase I clinical and pharmacokinetic (PK)/food effect study of oral CI- 1033, a pan-erb B tyrosine kinase inhibitor, in patients with advanced solid tumors, p.821, 2003.

A. Risch and C. Plass, Lung cancer epigenetics and genetics, International Journal of Cancer, vol.452, issue.1, pp.1-7, 2008.
DOI : 10.1002/ijc.23605

A. I. Robles, S. P. Linke, and C. C. Harris, The p53 network in lung carcinogenesis, Oncogene, vol.21, issue.45, pp.6898-907, 2002.
DOI : 10.1038/sj.onc.1205563

K. D. Rodland, N. Bollinger, D. Ippolito, L. K. Opresko, R. J. Coffey et al., Multiple Mechanisms Are Responsible for Transactivation of the Epidermal Growth Factor Receptor in Mammary Epithelial Cells, Journal of Biological Chemistry, vol.283, issue.46, pp.31477-87, 2008.
DOI : 10.1074/jbc.M800456200

S. J. Rogers, C. Box, P. Chambers, Y. Barbachano, C. M. Nutting et al., Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck, The Journal of Pathology, vol.271, issue.1, 2009.
DOI : 10.1002/path.2515

R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal et al., Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer, New England Journal of Medicine, vol.361, issue.10, pp.958-67, 2009.
DOI : 10.1056/NEJMoa0904554

R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla et al., Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer, Annals of Oncology, vol.19, issue.2, pp.362-371, 2008.
DOI : 10.1093/annonc/mdm474

H. Ross, G. Blumenschein, A. Dowlati, J. Aisner, A. Rigas et al., Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer, Journal of Clinical Oncology, vol.23, issue.16_suppl, p.7099, 2005.
DOI : 10.1200/jco.2005.23.16_suppl.7099

V. Rusch, J. Baselga, C. Cordon-cardo, J. Orazem, M. Zaman et al., Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung, Cancer Res, vol.53, pp.2379-85, 1993.

X. Saelens, N. Festjens, L. Vande-walle, M. Van-gurp, G. Van-loo et al., Toxic proteins released from mitochondria in cell death, Oncogene, vol.23, issue.16, pp.2861-74, 2004.
DOI : 10.1038/sj.onc.1207523

U. Sahin, G. Weskamp, K. Kelly, H. M. Zhou, S. Higashiyama et al., Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands, The Journal of Cell Biology, vol.347, issue.5, pp.769-79, 2004.
DOI : 10.1128/MCB.24.1.96-104.2004

Y. Saito, J. Haendeler, Y. Hojo, K. Yamamoto, and B. C. Berk, Receptor Heterodimerization: Essential Mechanism for Platelet-Derived Growth Factor-Induced Epidermal Growth Factor Receptor Transactivation, Molecular and Cellular Biology, vol.21, issue.19, pp.6387-94, 2001.
DOI : 10.1128/MCB.21.19.6387-6394.2001

H. Sakurai, T. Tsukamoto, C. A. Kjelsberg, L. G. Cantley, and S. K. Nigam, EGF receptor ligands are a large fraction of in vitro branching morphogens secreted by embryonic kidney, Am J Physiol, vol.273, issue.3 2, pp.463-72, 1997.

D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995.
DOI : 10.1016/1040-8428(94)00144-I

L. B. Saltz, H. J. Lenz, H. L. Kindler, H. S. Hochster, S. Wadler et al., Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study, Journal of Clinical Oncology, vol.25, issue.29, pp.4557-61, 2007.
DOI : 10.1200/JCO.2007.12.0949

L. B. Saltz, N. J. Meropol, P. J. Loehrer, . Sr, M. N. Needle et al., Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1209, 2004.
DOI : 10.1200/JCO.2004.10.182

M. Sanchez-cespedes, Dissecting the genetic alterations involved in lung carcinogenesis, Lung Cancer, vol.40, issue.2, pp.111-132, 2003.
DOI : 10.1016/S0169-5002(03)00033-3

V. Sapountzi, I. R. Logan, and C. N. Robson, Cellular functions of TIP60, The International Journal of Biochemistry & Cell Biology, vol.38, issue.9, pp.1496-509, 2006.
DOI : 10.1016/j.biocel.2006.03.003

U. A. Sartorius and P. H. Krammer, Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines, International Journal of Cancer, vol.56, issue.5, pp.584-92, 2002.
DOI : 10.1002/ijc.10096

J. D. Sato, T. Kawamoto, A. D. Le, J. Mendelsohn, J. Polikoff et al., Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors, Mol Biol Med, vol.1, issue.5, pp.511-540, 1983.

M. Sawada, P. Hayes, and S. Matsuyama, Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70, Nature Cell Biology, vol.5, issue.4, pp.352-359, 2003.
DOI : 10.1038/ncb955

J. H. Schiller, D. Harrington, C. P. Belani, C. Langer, A. Sandler et al., Comparison of Four Chemotherapy Regimens for Advanced Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.346, issue.2, pp.92-100, 2002.
DOI : 10.1056/NEJMoa011954

J. Schlessinger, Cell Signaling by Receptor Tyrosine Kinases, Cell, vol.103, issue.2, pp.211-236, 2000.
DOI : 10.1016/S0092-8674(00)00114-8

A. B. Schreiber, I. Lax, Y. Yarden, Z. Eshhar, and J. Schlessinger, Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor., Proceedings of the National Academy of Sciences, vol.78, issue.12, pp.7535-7544, 1981.
DOI : 10.1073/pnas.78.12.7535

D. S. Schrump, Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications, Clinical Cancer Research, vol.15, issue.12, pp.3947-57, 2009.
DOI : 10.1158/1078-0432.CCR-08-2787

L. Schuger, G. R. Johnson, K. Gilbride, G. D. Plowman, and R. Mandel, Amphiregulin in lung branching morphogenesis: interaction with heparan sulfate proteoglycan modulates cell proliferation. Development, pp.1759-67, 1996.

J. P. Sculier and D. Moro-sibilot, First- and second-line therapy for advanced nonsmall cell lung cancer, European Respiratory Journal, vol.33, issue.4, pp.915-945, 2009.
DOI : 10.1183/09031936.00132008

L. V. Sequist, D. W. Bell, T. J. Lynch, and D. A. Haber, Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.5, pp.587-95, 2007.
DOI : 10.1200/JCO.2006.07.3585

M. Heinemann and M. H. , Practical management of patients with non-small-cell lung cancer treated with gefitinib, J Clin Oncol, vol.23, issue.1, pp.165-74, 2005.

S. V. Sharma, D. W. Bell, J. Settleman, and D. A. Haber, Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, vol.64, issue.3, pp.169-81, 2007.
DOI : 10.1038/nrc2088

F. A. Shepherd, J. Rodrigues-pereira, T. Ciuleanu, E. H. Tan, V. Hirsh et al., Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-155, 2005.
DOI : 10.1056/NEJMoa050753

T. W. Shields, Surgical therapy for carcinoma of the lung, Clin Chest Med, vol.14, issue.1, pp.121-168, 1993.

N. Shivapurkar, J. Reddy, P. M. Chaudhary, and A. F. Gazdar, Apoptosis and lung cancer: A review, Journal of Cellular Biochemistry, vol.64, issue.5, pp.885-98, 2003.
DOI : 10.1002/jcb.10440

N. Shivapurkar, J. Reddy, H. Matta, U. G. Sathyanarayana, C. X. Huang et al., Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification, Oncogene, vol.21, issue.55, pp.8510-8514, 2002.
DOI : 10.1038/sj.onc.1205941

N. Shivapurkar, S. Toyooka, K. O. Toyooka, J. Reddy, K. Miyajima et al., Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types, International Journal of Cancer, vol.192, issue.5, pp.786-92, 2004.
DOI : 10.1002/ijc.20041

M. Shoyab, V. L. Mcdonald, J. G. Bradley, and G. J. Todaro, Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7., Proceedings of the National Academy of Sciences, vol.85, issue.17, p.6528, 1988.
DOI : 10.1073/pnas.85.17.6528

M. Sibilia and E. F. Wagner, Strain-dependent epithelial defects in mice lacking the EGF receptor, Science, vol.269, issue.5221, pp.234-242, 1995.
DOI : 10.1126/science.7618085

C. M. Silva, Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis, Oncogene, vol.23, issue.48, 2004.
DOI : 10.1038/sj.onc.1208159

N. Sizemore, A. D. Cox, J. A. Barnard, S. M. Oldham, E. R. Reynolds et al., Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor???related peptides, Gastroenterology, vol.117, issue.3, pp.567-76, 1999.
DOI : 10.1016/S0016-5085(99)70449-X

A. F. Sobrero, J. Maurel, L. Fehrenbacher, W. Scheithauer, Y. A. Abubakr et al., EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.14, pp.2311-2320, 2008.
DOI : 10.1200/JCO.2007.13.1193
URL : https://hal.archives-ouvertes.fr/inserm-00484211

M. A. Socinski, Antibodies to the Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab, Clinical Cancer Research, vol.13, issue.15, 2007.
DOI : 10.1158/1078-0432.CCR-07-0335

N. Solic and D. E. Davies, Differential Effects of EGF and Amphiregulin on Adhesion Molecule Expression and Migration of Colon Carcinoma Cells, Experimental Cell Research, vol.234, issue.2, pp.465-76, 1997.
DOI : 10.1006/excr.1997.3635

J. C. Soria, H. Y. Lee, J. I. Lee, L. Wang, J. P. Issa et al., Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation, Clin Cancer Res, vol.8, issue.5, pp.1178-84, 2002.

J. Soria, J. Cortes, J. Armand, A. Taleb, L. Van-bree et al., Phase I pharmacokinetic profile and early clinical evaluation of the PAN-HER inhibitor BMS-599626, Journal of Clinical Oncology, vol.23, issue.16_suppl, p.3109, 2005.
DOI : 10.1200/jco.2005.23.16_suppl.3109

D. C. Spierings, E. G. De-vries, W. Timens, H. J. Groen, H. M. Boezen et al., Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors, Clin Cancer Res, vol.9, issue.9, pp.3397-405, 2003.

S. G. Spiro and J. C. Porter, Lung Cancer???Where Are We Today?, American Journal of Respiratory and Critical Care Medicine, vol.166, issue.9, pp.1166-96, 2002.
DOI : 10.1164/rccm.200202-070SO

H. Steller, Mechanisms and genes of cellular suicide, Science, vol.267, issue.5203, pp.1445-1454, 1995.
DOI : 10.1126/science.7878463

H. R. Stennicke and G. S. Salvesen, Caspases ??? controlling intracellular signals by protease zymogen activation, Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, vol.1477, issue.1-2, pp.299-306, 2000.
DOI : 10.1016/S0167-4838(99)00281-2

M. D. Sternlicht, S. W. Sunnarborg, H. Kouros-mehr, Y. Yu, D. C. Lee et al., Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin, Development, vol.132, issue.17, pp.3923-3956, 2005.
DOI : 10.1242/dev.01966

T. E. Stinchcombe and M. A. Socinski, Current Treatments for Advanced Stage Non-Small Cell Lung Cancer, Proceedings of the American Thoracic Society, vol.6, issue.2, pp.233-274, 2009.
DOI : 10.1513/pats.200809-110LC

C. Subramanian, J. A. Jarzembowski, A. W. Opipari, . Jr, V. P. Castle et al., CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A. Neoplasia, pp.495-503, 2007.

C. Subramanian, A. W. Opipari, . Jr, X. Bian, V. P. Castle et al., Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors, Proceedings of the National Academy of Sciences, vol.102, issue.13, pp.4842-4849, 2005.
DOI : 10.1073/pnas.0408351102

C. Subramanian, A. W. Opipari, . Jr, V. P. Castle, and R. P. Kwok, Histone Deacetylase Inhibition Induces Apoptosis in Neuroblastoma, Cell Cycle, vol.4, issue.12, pp.1741-1744, 2005.
DOI : 10.4161/cc.4.12.2212

S. W. Sunnarborg, C. L. Hinkle, M. Stevenson, W. E. Russell, C. S. Raska et al., Tumor Necrosis Factor-?? Converting Enzyme (TACE) Regulates Epidermal Growth Factor Receptor Ligand Availability, Journal of Biological Chemistry, vol.277, issue.15, pp.12838-12883, 2002.
DOI : 10.1074/jbc.M112050200

S. A. Susin, H. K. Lorenzo, N. Zamzami, I. Marzo, B. E. Snow et al., Molecular characterization of mitochondrial apoptosis-inducing factor, Nature, vol.397, issue.6718, pp.441-447, 1999.

K. Sutheesophon, Y. Kobayashi, M. A. Takatoku, K. Ozawa, Y. Kano et al., Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib, Acta Haematologica, vol.115, issue.1-2, pp.1-2, 2006.
DOI : 10.1159/000089471

J. Tabernero, E. Van-cutsem, E. Diaz-rubio, A. Cervantes, Y. Humblet et al., Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.25, issue.33, pp.5225-5257, 2007.
DOI : 10.1200/JCO.2007.13.2183

S. W. Tait and D. R. Green, Caspase-independent cell death: leaving the set without the final cut, Oncogene, vol.4, issue.50, pp.6452-61, 2008.
DOI : 10.1016/j.ejca.2007.01.029

Y. Tang, J. Luo, W. Zhang, and W. Gu, Tip60-Dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis, Molecular Cell, vol.24, issue.6, pp.827-866, 2006.
DOI : 10.1016/j.molcel.2006.11.021

W. G. Tatton, R. Chalmers-redman, D. Brown, and N. Tatton, Apoptosis in Parkinson's disease: Signals for neuronal degradation, Annals of Neurology, vol.60, issue.S3, 2003.
DOI : 10.1002/ana.10489

N. Thatcher, A. Chang, P. Parikh, J. Rodrigues-pereira, T. Ciuleanu et al., Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), The Lancet, vol.366, issue.9496, pp.1527-1564, 2005.
DOI : 10.1016/S0140-6736(05)67625-8

T. Van-den-broeck and A. , Aspects épigénétiques des cancers broncho-pulmonaires et implication de l'histone acétyltransférase Tip60, Ph.D, 2009.

L. Thiberville and C. Paris, Epidémiologie et facteurs de risque des cancers bronchiques primitifs, EMCpneumologie, vol.1, issue.1, pp.7-18, 2004.

S. M. Thomas, N. E. Bhola, Q. Zhang, S. C. Contrucci, A. L. Wentzel et al., Cross-talk between G Protein-Coupled Receptor and Epidermal Growth Factor Receptor Signaling Pathways Contributes to Growth and Invasion of Head and Neck Squamous Cell Carcinoma, Cancer Research, vol.66, issue.24, pp.11831-11840, 2006.
DOI : 10.1158/0008-5472.CAN-06-2876

M. Thome and J. Tschopp, Regulation of lymphocyte proliferation and death by flip, Nature Reviews Immunology, vol.281, issue.1, pp.50-58, 2001.
DOI : 10.1038/35095508

C. B. Thompson, Apoptosis in the pathogenesis and treatment of disease, Science, vol.267, issue.5203, pp.1456-62, 1995.
DOI : 10.1126/science.7878464

D. W. Threadgill, A. A. Dlugosz, L. A. Hansen, T. Tennenbaum, U. Lichti et al., Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype, Science, vol.269, issue.5221, pp.230-234, 1995.
DOI : 10.1126/science.7618084

N. Torring, B. S. Sorensen, S. T. Bosch, H. Klocker, and E. Nexo, Amphiregulin is expressed in primary cultures of prostate myofibroblasts, fibroblasts, epithelial cells, and in prostate tissue, Prostate Cancer and Prostatic Diseases, vol.1, issue.5, pp.262-267, 1998.
DOI : 10.1038/sj.pcan.4500250

S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B. E. Johnson et al., Gefitinib Induces Apoptosis in the EGFRL858R Non-Small-Cell Lung Cancer Cell Line H3255, Cancer Research, vol.64, issue.20, pp.7241-7245, 2004.
DOI : 10.1158/0008-5472.CAN-04-1905

W. D. Travis, E. Brambilla, H. K. Yang, M. J. Chang, H. J. Yen et al., WHO Classification of tumors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients, Lung Cancer, 2004.

M. S. Tsao, A. Sakurada, J. C. Cutz, C. Q. Zhu, S. Kamel-reid et al., Erlotinib in Lung Cancer ??? Molecular and Clinical Predictors of Outcome, New England Journal of Medicine, vol.353, issue.2, pp.133-177, 2005.
DOI : 10.1056/NEJMoa050736

F. Tsuruta, J. Sunayama, Y. Mori, S. Hattori, S. Shimizu et al., JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins, The EMBO Journal, vol.15, issue.8, pp.1889-99, 2004.
DOI : 10.1038/sj.emboj.7600194

H. Ushiro and S. Cohen, Identification of phosphotyrosine as a product of epidermal growth factoractivated protein kinase in A-431 cell membranes, J Biol Chem, vol.255, issue.18, pp.8363-8368, 1980.

S. Van-cruchten and W. Van-den-broeck, Morphological and Biochemical Aspects of Apoptosis, Oncosis and Necrosis, Anatomia, Histologia, Embryologia: Journal of Veterinary Medicine Series C, vol.68, issue.4, pp.214-237, 2002.
DOI : 10.1093/emboj/16.17.5386

S. Vignot and B. Besse, [Gemcitabine and non small-cell lung cancer]. Bull Cancer, Spec No Actualites S95-103, 2007.

X. D. Wang, K. Reeves, F. R. Luo, L. A. Xu, F. Lee et al., Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring, Genome Biology, vol.8, issue.11, p.255, 2007.
DOI : 10.1186/gb-2007-8-11-r255

X. Wang, S. Masri, S. Phung, and S. Chen, The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop, Cancer Research, vol.68, issue.7, pp.2259-65, 2008.
DOI : 10.1158/0008-5472.CAN-07-5544

W. H. Ward, P. N. Cook, A. M. Slater, D. H. Davies, G. A. Holdgate et al., Epidermal growth factor receptor tyrosine kinase, Biochemical Pharmacology, vol.48, issue.4, pp.659-66, 1994.
DOI : 10.1016/0006-2952(94)90042-6

R. Weber, ULTRASTRUCTURAL CHANGES IN REGRESSING TAIL MUSCLES OF XENOPUS LARVAE AT METAMORPHOSIS, The Journal of Cell Biology, vol.22, issue.2, pp.481-488, 1964.
DOI : 10.1083/jcb.22.2.481

M. Weil, M. C. Raff, and V. M. Braga, Caspase activation in the terminal differentiation of human epidermal keratinocytes, Current Biology, vol.9, issue.7, pp.361-365, 1999.
DOI : 10.1016/S0960-9822(99)80162-6

S. Ettinger and E. David, Thoracic Oncology, Part I-2 : The epidemiology of Lung Cancer, 2001.

N. E. Willmarth and S. P. Ethier, Autocrine and Juxtacrine Effects of Amphiregulin on the Proliferative, Invasive, and Migratory Properties of Normal and Neoplastic Human Mammary Epithelial Cells, Journal of Biological Chemistry, vol.281, issue.49, pp.37728-37765, 2006.
DOI : 10.1074/jbc.M606532200

S. E. Witta, R. Dziadziuszko, K. Yoshida, K. Hedman, M. Varella-garcia et al., ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC), Annals of Oncology, vol.20, issue.4, pp.689-95, 2009.
DOI : 10.1093/annonc/mdn703

S. E. Witta, R. M. Gemmill, F. R. Hirsch, C. D. Coldren, K. Hedman et al., Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines, Cancer Research, vol.66, issue.2, pp.944-50, 2006.
DOI : 10.1158/0008-5472.CAN-05-1988

W. Wood, M. Turmaine, R. Weber, V. Camp, R. A. Maki et al., Mesenchymal cells engulf and clear apoptotic footplate cells in macrophageless PU.1 null mouse embryos. Development, pp.5245-52, 2000.

M. Wu, A. Rivkin, and T. Pham, Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer, Clinical Therapeutics, vol.30, issue.1, pp.14-30, 2008.
DOI : 10.1016/j.clinthera.2008.01.014

W. G. Wu, J. C. Soria, L. Wang, B. L. Kemp, and L. Mao, TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer, Anticancer Res, vol.20, issue.6B, pp.4525-4534, 2000.

M. Xin, F. Gao, W. S. May, T. Flagg, and X. Deng, Protein Kinase C?? Abrogates the Proapoptotic Function of Bax through Phosphorylation, Journal of Biological Chemistry, vol.282, issue.29, pp.21268-77, 2007.
DOI : 10.1074/jbc.M701613200

M. Yamada, Y. Ichikawa, S. Yamagishi, N. Momiyama, M. Ota et al., Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer, Clinical Cancer Research, vol.14, issue.8, pp.2351-2357, 2008.
DOI : 10.1158/1078-0432.CCR-07-4499

S. Yamane, S. Ishida, Y. Hanamoto, K. Kumagai, R. Masuda et al., Proinflammatory role of amphiregulin, an epidermal growth factor family member whose expression is augmented in rheumatoid arthritis patients, Journal of Inflammation, vol.5, issue.1, p.5, 2008.
DOI : 10.1186/1476-9255-5-5

Y. Yarden and M. X. Sliwkowski, Untangling the ErbB signalling network, Nature Reviews Molecular Cell Biology, vol.2, issue.2, pp.127-164, 2001.
DOI : 10.1038/35052073

K. Yonesaka, K. Zejnullahu, N. Lindeman, A. J. Homes, D. M. Jackman et al., Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers, Clinical Cancer Research, vol.14, issue.21, pp.6963-73, 2008.
DOI : 10.1158/1078-0432.CCR-08-0957

J. Y. Yoo, J. H. Kim, J. Kim, J. H. Huang, S. N. Zhang et al., Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition, Gene Therapy, vol.73, issue.9, pp.635-51, 2008.
DOI : 10.1038/sj.bjc.6690811

H. Zembutsu, Y. Ohnishi, Y. Daigo, T. Katagiri, T. Kikuchi et al., Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839, International Journal of Oncology, vol.23, issue.1, pp.29-39, 2003.
DOI : 10.3892/ijo.23.1.29

W. Zhang, M. Peyton, Y. Xie, J. Soh, J. D. Minna et al., Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines, Journal of Thoracic Oncology, vol.4, issue.2, pp.161-167, 2009.
DOI : 10.1097/JTO.0b013e318194fae7

Q. Zhou, S. Snipas, K. Orth, M. Muzio, V. M. Dixit et al., Target Protease Specificity of the Viral Serpin CrmA: ANALYSIS OF FIVE CASPASES, Journal of Biological Chemistry, vol.272, issue.12, pp.7797-800, 1997.
DOI : 10.1074/jbc.272.12.7797

S. Zochbauer-muller, A. F. Gazdar, and J. D. Minna, Molecular Pathogenesis of Lung Cancer, Annual Review of Physiology, vol.64, issue.1, pp.681-708, 2002.
DOI : 10.1146/annurev.physiol.64.081501.155828